METHODS OF COLCHICINE ADMINISTRATION
1 Assignment
0 Petitions
Accused Products
Abstract
The invention provides improved methods for coadministration of colchicine with drugs metabolized by CYP3A4 (anciently referred to as cytochrome P450 isozyme 3A4) or the P-glycoprotein transporter, but not both. The method enables non-toxic coadministration of colchicine and the second drug at their ordinary levels safely and effectively without reducing the dose or frequency for either drug.
6 Citations
32 Claims
-
1-20. -20. (canceled)
-
21. A method of treating a patient for an inflammatory disorder, wherein the inflammatory disorder is chronic gout, familial Mediterranean fever or Behç
- et'"'"'s disease, with colchicine while concomitantly administering a second drug that is not an inhibitor of the cytochrome P450 3A4 isoenzyme (CYP3A4) but is an inhibitor of P-glycoprotein 1 (P-gp), wherein the second drug is propafenone, wherein the method comprises;
a) administering to the patient a therapeutically effective fixed maintenance dose of colchicine in an amount of from about 0.6 to about 1.2 mg/day, for a maintenance period of a plurality of days, without administering propafenone; b) after step (a), administering to the patient one or more therapeutically effective doses of propafenone; and c) concomitantly with step (b), administering to the patient the fixed maintenance dose of colchicine of step (a) without dose reduction. - View Dependent Claims (22, 23, 24, 25, 26, 27)
- et'"'"'s disease, with colchicine while concomitantly administering a second drug that is not an inhibitor of the cytochrome P450 3A4 isoenzyme (CYP3A4) but is an inhibitor of P-glycoprotein 1 (P-gp), wherein the second drug is propafenone, wherein the method comprises;
-
28. A method of treating a patient for an inflammatory disorder, wherein the inflammatory disorder is chronic gout, familial Mediterranean fever or Behç
- et'"'"'s disease, by administering colchicine while concomitantly administering an inhibitor of P-glycoprotein 1 (P-gp) that is not an inhibitor of the cytochrome P450 3A4 isoenzyme (CYP3A4), wherein the inhibitor of P-gp is propafenone, wherein the method comprises;
a) administering to the patient a plurality of therapeutically effective doses of propafenone for a plurality of days without administering colchicine; b) after step (a), administering to the patient one or more fixed maintenance doses of colchicine in an amount from about 0.6 to about 1.2 mg/day; c) concomitantly with step (b) administering to the patient a plurality of effective doses of propafenone; d) after step (c), discontinuing administration of propafenone and continuing to administer the fixed maintenance doses of colchicine administered in step (b) without dose adjustment. - View Dependent Claims (29, 30, 31, 32)
- et'"'"'s disease, by administering colchicine while concomitantly administering an inhibitor of P-glycoprotein 1 (P-gp) that is not an inhibitor of the cytochrome P450 3A4 isoenzyme (CYP3A4), wherein the inhibitor of P-gp is propafenone, wherein the method comprises;
Specification